Topic

Articles

Gilead's pricing of COVID drug remdesivir is a reminder of pharma's tenuous path forward as it seeks a more holistic image makeover.

Will the Industry Rise to the Occasion?

Jill Wechsler is Pharm Exec's Washington Corespondent

While scientists are striving to discover and produce safe and effective vaccines to halt the coronovirus outbreak, anti-vacciners are revving up misinformation campaigns.

Vaccine “Hesitancy” Threatens COVID Immunization Efforts

Welcome to the new look and branding of Pharmaceutical Executive-reimagined to better reflect you, our audience, and expand on the content you've long trusted us to deliver.   

Master the Science of Success

Anil Soni is Head of Global Infectious Diseases at Mylan. He was closely involved in the early years of the Global Fund to Fight AIDS, Tuberculosis and Malaria, serving as the Advisor to the Executive Director from 2002-2004 and the Founding Executive Director of Friends of the Global Fight, in Washington, DC, from 2004-2005. He later served as the Chief Executive Officer of the Clinton Health Access Initiative.Ya’ir Aizenman is US and European Director for Infectious Disease at Mylan. Prior to Mylan, he was a Franklin Fellow with the U.S. Department of State, where he worked alongside colleagues in the office of the Senior Advisor for International Development and the President’s Emergency Program for AIDS Relief. 

The US could theoretically treat every single American living with HIV without spending an extra dollar on drugs. And President Trump can broker a deal to do it, write Anil Soni and Ya’ir Aizenman.

A Bold Deal Could Help Trump Administration End HIV in America

Tom Kottler is co-founder and Chief Executive Officer of HealthPrize Technologies, the leading digital adherence and patient engagement platform for life science companies. Kottler has led multiple high-growth organizations during his career, including Advanced BioHealing, which was acquired by Shire for $750 million, and MedAptus, an innovative healthcare IT company based in Boston, Mass.

Outside of raising prices, pharma can generate new revenue from just three other sources, write Tom Kottler.

Time is Running Out for Pharma to Change Course

Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.

Innovating Around Innovation

Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.

Get Back in the Box!

Social media now gives companies a plethora of creative ways to digitally spread recent company news and keep customers informed

Giving Press Releases New Legs

HTAs are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes.

Europe in HTA Gridlock

The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance

Opinion